These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38785334)

  • 21. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
    Portron A; Jadidi S; Sarkar N; DiMarchi R; Schmitt C
    Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study.
    Li Y; Toyama K; Nakatsu T; Ishizuka H; Wu H; Cao G; Yu J; Wang Y; Liu X; Guo B; Wu J; Yu P; Hong Z; Zhang J; Wu X
    Adv Ther; 2023 Apr; 40(4):1628-1643. PubMed ID: 36790683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers.
    Pratt RD; Swinkels DW; Ikizler TA; Gupta A
    J Clin Pharmacol; 2017 Mar; 57(3):312-320. PubMed ID: 27557937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers.
    Jansen M; Warrington S; Dishy V; Ohwada S; Johnson L; Brown K; Ishizuka H
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):661-669. PubMed ID: 29663714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
    Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
    J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers.
    Porter JB; Scrimgeour A; Martinez A; James L; Aleku M; Wilson R; Muckenthaler M; Boyce M; Wilkes D; Schaeper U; Campion GV
    Am J Hematol; 2023 Sep; 98(9):1425-1435. PubMed ID: 37497888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects.
    Hall J; Gillen M; Liu S; Miner JN; Valdez S; Shen Z; Lee C
    Drug Des Devel Ther; 2018; 12():1799-1807. PubMed ID: 29950814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study.
    Chen Q; Hu C; Liu Y; Song R; Zhu W; Zhao H; Nino A; Zhang F; Liu Y
    PLoS One; 2018; 13(6):e0197984. PubMed ID: 29933364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
    Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers.
    Ackaert O; Vanhoutte F; Verpoorten N; Buelens A; Lachau-Durand S; Lammens L; Hoetelmans R; Van Loock M; Herrera-Taracena G
    Clin Infect Dis; 2023 Sep; 77(6):857-865. PubMed ID: 37161721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers.
    Grippo JF; Folitar I; Passe S; Jiang Q; Rodriguez I; Fettner SH; Calleja E
    Clin Transl Sci; 2021 Jul; 14(4):1524-1534. PubMed ID: 33742764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects.
    Boyce M; Warrington S; Cortezi B; Zöllner S; Vauléon S; Swinkels DW; Summo L; Schwoebel F; Riecke K
    Br J Pharmacol; 2016 May; 173(10):1580-8. PubMed ID: 26773325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects.
    Takizawa M; Cerneus D; Michon I; Rijnders S; van der Heide D; Meijer J; Stoelzel M; Sato Y
    Adv Ther; 2020 Sep; 37(9):3878-3900. PubMed ID: 32681461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies.
    Cahn A; Tal-Singer R; Pouliquen IJ; Mehta R; Preece A; Hardes K; Crater G; Deans A
    Clin Drug Investig; 2013 Jul; 33(7):477-88. PubMed ID: 23784369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
    Tarral A; Dostert P; Guillevic Y; Fabbri L; Rondelli I; Mariotti F; Imbimbo BP
    J Clin Pharmacol; 2003 Aug; 43(8):901-11. PubMed ID: 12953347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Ford J; Lawson M; Fowler D; Maruyama N; Mito S; Tomiyasu K; Kinoshita S; Suzuki C; Kawaguchi A; Round P; Boyce M; Warrington S; Weber W; van Deventer S; Kastelein JJ
    Br J Clin Pharmacol; 2014 Sep; 78(3):498-508. PubMed ID: 24628035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
    Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
    J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.